Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 3, 2002, Pages 288-293

  Poland, Russell A ^a,b,c   Lin, Keh Ming ^a,b,c   Nuccio, Cenci ^a,b,c   Wilkinson, Grant R ^a,b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CHLORZOXAZONE; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DRUG METABOLITE; MIDAZOLAM;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIET; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX; UNITED STATES; WEIGHT;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; LOS ANGELES; MALE; MEXICAN AMERICANS; MIDAZOLAM; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; STATISTICS, NONPARAMETRIC;

EID: 0036738084     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.127398     Document Type: Article

References (31)

1. Ethnic differences in drug disposition and responsiveness
2. Clinical trials and transethnic pharmacology
3. Molecular basis of ethnic differences in drug disposition and response
4. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians
5. Genetic and dietary predictors of CYP2E1 activity: A phenotyping study in Hawaii Japanese using chlorzoxazone
6. CYP3A activity in European-American and Japanese men using midazolam as an in vivo probe
7. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism
8. Ethnic differences in the pharmacokinetics of oral nifedipine
9. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine
10. Factors affecting the absolute bioavailability of nifedipine
11. Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians and South Asians
12. Pharmacokinetics of oral nifedipine in different population
13. Interethnic variability in nifedipine disposition: Reduced systemic plasma clearance in Mexican subjects
14. Pharmacokinetics of midazolam in Mexicans: Evidence for interethnic variability
15. Origins of US Hispanics: Implications for disease
16. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms
17. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone - A putative probe for CYP2E1 activity
18. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans
19. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
20. Cytochrome P450IIE1: Roles in nitrosamine metabolism and mechanisms of regulation
21. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodiaikylamines and tobacco-related nitrosamines in human liver microsomes
22. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
23. Gender effects in pharmacokinetics and pharmacodynamics
24. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
25. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance
26. Bioavailability of oral cyclosporine in healthy Mexican volunteers: Evidence for interethnic variability
27. P-glycoprotein and cytochrome P4503A inhibition: Dissociation of inhibitory potencies
28. Dose dependent pharmacokinetics of midazolam
29. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin